Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Short term Debt (2020 - 2025)

Bioventus' Short term Debt history spans 6 years, with the latest figure at $11.2 million for Q3 2025.

  • For Q3 2025, Short term Debt fell 70.83% year-over-year to $11.2 million; the TTM value through Sep 2025 reached $11.2 million, down 70.83%, while the annual FY2024 figure was $27.3 million, N/A changed from the prior year.
  • Short term Debt reached $11.2 million in Q3 2025 per BVS's latest filing, down from $43.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $43.4 million in Q2 2025 to a low of $11.2 million in Q3 2025.
  • Average Short term Debt over 5 years is $26.2 million, with a median of $24.9 million recorded in 2022.
  • Peak YoY movement for Short term Debt: skyrocketed 240.69% in 2024, then plummeted 70.83% in 2025.
  • A 5-year view of Short term Debt shows it stood at $18.0 million in 2021, then soared by 83.26% to $33.1 million in 2022, then plummeted by 40.76% to $19.6 million in 2023, then surged by 39.6% to $27.3 million in 2024, then plummeted by 58.85% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Short term Debt are $11.2 million (Q3 2025), $43.4 million (Q2 2025), and $37.3 million (Q1 2025).